MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on July 17, 2006; DOI: 10.1124/mol.106.022624

0026-895X/06/7004-1390-1394$20.00
Mol Pharmacol 70:1390-1394, 2006

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.022624v1
70/4/1390    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holzer, A. K.
Right arrow Articles by Howell, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holzer, A. K.
Right arrow Articles by Howell, S. B.

Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin

Alison K. Holzer, Gerald H. Manorek, and Stephen B. Howell

Department of Medicine and the Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, California

Received for publication January 16, 2006.

Accepted for publication July 17, 2006.


   Abstract
Top
 Abstract
Materials and Methods
 Results
 Discussion
 References
 
The goal of this study was to determine the ability of the major copper influx transporter CTR1 to mediate the cellular accumulation of cisplatin (DDP), carboplatin (CBDCA), and oxaliplatin (L-OHP). Wild-type murine embryonic fibroblasts (CTR1+/+) and a subline in which both alleles of CTR1 were deleted (CTR1-/-) were tested for their ability to accumulate platinum when exposed to increasing concentrations of DDP, CBDCA, or L-OHP for 1 h. They were also tested for their sensitivity to the growth-inhibitory effect of each drug. Platinum content was measured by ion-coupled plasmon mass spectroscopy. The experimental model was validated by measuring copper accumulation and cytotoxicity. CTR1-/- cells accumulated only 5.7% as much copper as CTR1+/+ cells during a 1-h exposure to 2 µM copper. When exposed to DDP, CBDCA, or L-OHP at 2 µM, accumulation in the CTR1-/- cells was only 35 to 36% of that in the CTR1+/+ cells. When tested at a 5-fold higher concentration, this deficit remained for DDP and CBDCA, but accumulation of L-OHP was no longer CTR1-dependent. There was an association between the effect of loss of CTR1 function on uptake of the platinum drugs and their cytotoxicity. The CTR1-/- cells were 3.2-fold resistant to DDP, 2.0-fold resistant to CBDCA, but only 1.7-fold resistant to L-OHP. Thus, whereas CTR1 controls the cellular accumulation of all three drugs at low concentrations, accumulation of L-OHP is not dependent on CTR1 at higher concentrations. We conclude that L-OHP is a substrate for some other cellular entry mechanism, a feature consistent with its different clinical spectrum of activity.

Cisplatin (DDP), carboplatin (CBDCA), and oxaliplatin (L-OHP) are important chemotherapeutic agents, but the development of resistance during therapy is a common occurrence for all three. Several mechanisms that can contribute to resistance have been identified previously (Siddik, 2003Go); however, the molecular mechanisms are not well defined. Whereas the development of resistance is believed to be multifactorial, the most commonly identified defect is decreased drug accumulation (Andrews and Howell, 1990Go; Andrews et al., 1990Go; Gately and Howell, 1993Go). The reasons for decreased accumulation are unknown in part due to the fact that the pathways by which these platinum-containing drugs enter and exit from cells are defined poorly. The platinum drugs enter cells much more slowly than most other classes of small-molecule anticancer agents; current evidence suggests that one component of their uptake is mediated by a transporter or channel (Gately and Howell, 1993Go). Many other metal ions enter cells on specific transporters, and acquisition of resistance to DDP is often accompanied by resistance to other metalloids (Tobey and Tesmer, 1985Go; Naredi et al., 1995Go; Romach et al., 2000Go). In particular, cells selected for resistance to DDP are often cross-resistant to copper and vice versa (Katano et al., 2002Go; Safaei et al., 2004bGo). Recent studies from this and other laboratories have demonstrated that both copper efflux transporters ATP7A and ATP7B modulate the export of DDP (Safaei et al., 2004aGo; Samimi et al., 2004aGo).

Copper transporter 1 (CTR1) is the major copper influx transporter. Deletion of the yCTR1 gene in Saccharomyces cerevisiae markedly reduces the accumulation of all three clinically available platinum-containing chemotherapeutic agents (Ishida et al., 2002Go; Lin et al., 2002Go). A preliminary study suggested that the cellular accumulation of DDP was also impaired in embryonic fibroblasts established from mice in which both mCTR1 alleles had been disrupted (Ishida et al., 2002Go). Forced overexpression of hCTR1 in human ovarian carcinoma cells enhanced DDP uptake (Holzer et al., 2003Go). Increased hCTR1 expression in human small-cell lung cancer cells (Song et al., 2004Go) was reported to enhance the uptake of DDP, CBDCA, and L-OHP but overexpression of hCTR1 in human squamous carcinoma cells was reported to have no effect on DDP uptake (Beretta et al., 2004Go). Such forced overexpression of hCTR1 is toxic to human cells, and it is not clear that CTR1 functions normally at such high intracellular levels, as evidenced by the finding that increased CTR1 expression and DDP uptake into the whole cell is accompanied by minimal change in sensitivity to the cytotoxic effect of the drug and DNA adduct formation (Holzer et al., 2004Go).

The amino acid sequence of murine CTR1 shares 92% homology with human CTR1 (Kuo et al., 2001Go). Whereas deletion of both mCTR1 alleles produced embryonic lethality, CTR1+/+ and CTR1-/- embryo fibroblast cell lines were successfully established from the parental and knockout mice (Lee et al., 2001Go). To refine understanding of how CTR1 modulates the cellular pharmacology of the platinum-containing drugs, we carried out further investigations using this isogenic pair of mouse embryo fibroblasts. We report here quantitative studies of the effect of loss of mCTR1 function on cellular accumulation of the three clinically used platinum-containing drugs and on sensitivity to the cytotoxic effects of these agents. The results indicate that CTR1 regulates the cellular accumulation of all three drugs at concentrations attainable in humans but that at 5-fold higher concentrations, although accumulation of DDP and CBDCA is still CTR1-dependent, L-OHP accumulation becomes CTR1-independent, indicating that it is a substrate for another cell-entry mechanism.


   Materials and Methods
Top
 Abstract
 Materials and Methods
Results
 Discussion
 References
 
Reagents. DDP was a gift from Bristol-Myers Squibb (Princeton, NJ). The clinical formulation (Platinol-AQ) containing 3.33 mM DDP was kept in the dark at room temperature. A 100 µM stock was created by diluting the drug in 0.9% NaCl. CBDCA was purchased from Sigma (St. Louis, MO), and a stock solution was prepared at 10 mM in water. L-OHP was a generous gift from Sanofi Pharmaceuticals (Malvern, PA). A stock solution was prepared at 10 mM in water. Copper in the form of cupric sulfate was obtained from Fisher Scientific (Tustin, CA). Protein concentration was measured using Bradford's reagent from Bio-Rad Inc. (Hercules, CA). 64CuSO4 was purchased from the Mallinckrodt Institute of Radiology (Washington University Medical School, St. Louis, MO).

Cell Lines. The murine embryonic fibroblasts, originally isolated from day-7 embryos and immortalized using SV40 large T antigen, were cultured as described previously (Lee et al., 2002Go). Cells were grown in 20% fetal bovine serum, 2 mM glutamine, 1x nonessential amino acids, 55 µM 2-mercaptoethanol, 50 mg/liter uridine, and 110 mg/ml pyruvate.

Measurement of 64Cu Accumulation. Copper uptake measurements were made using cell cultures that were 80% confluent in the 30 mm wells of a six-well plate. After the addition of prewarmed media containing 2 µM 64CuSO4, the plates were incubated at 37°C in 5% CO2 for 30 min. At the end of the incubation period, the plates were placed on ice, and the wells were rinsed three times with 3 ml of ice-cold phosphate-buffered saline. Cell lysis buffer (0.1% Triton-X and 1% SDS in phosphate-buffered saline) in a volume of 500 µl was added to the wells, and the lysate was harvested by scraping the dish twice before it was transferred to tubes for {gamma} counting on a Beckman Gamma 5500B (Beckman Coulter, Fullerton, CA). Six cultures were harvested for each data point. Lysates from a set of identical cultures not exposed to 64CuSO4 were used to measure protein concentration.

Platinum Accumulation Assays. Cells were plated in sixwell plates in media without any drugs. Once the cultures were 80% confluent, 2 or 10 µM DDP, 2, 10, or 12 µM CBDCA, or 2, 6, or 10 µM L-OHP was added, and plates were incubated at 37°C in 5% CO2 for 1 h. The plates were then placed on ice, and wells were rinsed three times with 3 ml of ice-cold phosphate-buffered saline. Cells were harvested by dissolving them in 70% nitric acid at 65°C for at least 2 h. Samples were diluted to 5% nitric acid with water containing 1 ppb indium and 0.1% Triton X-100. Platinum content was determined using inductively coupled plasmon mass spectroscopy (Element2; PerkinElmer Life Sciences, Boston, MA) on an instrument available through the Analytical Facility at the Scripps Institute of Oceanography (San Diego, CA). Lysates from a set of identical cultures suspended in 0.1% Triton X-100 and 1% SDS in phosphate-buffered saline were used to measure protein concentration.

Drug Sensitivity Assay. Six-well plates were seeded with 1000 cells per well, and 24 h later, the medium was replaced with medium containing various concentrations of either DDP, CBDCA, L-OHP, or copper. After 3 days of continuous exposure, cultures were trypsinized and stained with trypan blue. The number of live cells per well was determined by counting cells that excluded trypan blue with a hemocytometer. Each drug concentration was tested in six cultures per cell line, and each experiment was repeated three times.

Statistics. Tests of significance used a two-sided paired Student's t test with the assumption of unequal variance; p values of <0.05 were considered significant. All p values are for the comparison of the values for the CTR1+/+ versus the CTR1-/- cells.


   Results
Top
 Abstract
 Materials and Methods
 Results
Discussion
 References
 
Effect of the Loss of CTR1 on Copper Accumulation. Previous studies have shown that CTR1 plays a substantial role in the cellular accumulation of copper. To verify the influence of CTR1 on copper uptake and validate this cell line model for the study of the platinum-containing drugs, CTR1+/+ and CTR1-/- cells were exposed to a 2 µM concentration of 64Cu for 1 h and then washed extensively before the accumulation of copper was measured by {gamma} counting. This concentration of copper is near the Km value of 1 µM reported for murine CTR1 (Lee et al., 2002Go). As shown in Table 1, the cells lacking CTR1-/- accumulated only 5.7% as much copper as the CTR1+/+ cells. Thus, as reported previously (Lee et al., 2002Go), loss of CTR1 markedly impaired the influx of copper in these cells.


View this table:
[in this window]
[in a new window]

  		TABLE 1 Accumulation of copper, DDP, CBDCA, and L-OHP in CTR1-/- cells as a percentage of that in CTR1+/+ cells

Data are presented as mean ± S.E.M.

 

Effect of the Loss of CTR1 on DDP, CBDCA, and L-OHP Accumulation. The accumulation of the platinum-containing drugs was quantified by measuring the platinum content of the whole cell after a 1-h exposure to either 2 or 10 µM DDP, CBDCA, or L-OHP or concentrations that were found to be equitoxic to human ovarian carcinoma cells in clonogenic assays performed in an earlier study (Samimi et al., 2004bGo). The equitoxic concentrations of the drugs were 2 µM for DDP, 12 µM for CBDCA, and 6 µM for L-OHP. This resulted in data on the accumulation in CTR1+/+ and CTR1-/- cells being available for two concentrations of DDP and three concentrations for CBDCA and L-OHP. As shown in Table 1, when exposed to 2 µM DDP for 1 h, the CTR1-/- cells accumulated only 36.3% as much platinum as the CTR1+/+ cells. The magnitude of the effect of the loss of CTR1 expression was no less when the accumulation was measured after a 1-h exposure to 10 µM DDP. A similar pattern was observed for CBDCA. When exposed to a concentration of 2 µM, the CTR1-/- cells accumulated only 35.1% as much platinum as the CTR1+/+ cells, and the magnitude of this deficit was only slightly less at 10 or 12 µM. However, L-OHP exhibited a different pattern. When the cells were exposed to 2 µM L-OHP, the loss of CTR1 had a substantial effect, and the accumulation in the CTR1-/- cells was only 36.3% of that in the CTR1+/+ cells. However, as the concentration of L-OHP was increased first to 6 and then to 10 µM, the magnitude of the effect of the loss of CTR1 diminished to the point at which there was no deficit at 10 µM.


Figure 1
View larger version (12K):
[in this window]
[in a new window]

  		Fig. 1. Inhibition of the growth of CTR1+/+ and CTR1-/- cells by DDP, CBDCA, and L-OHP. Each curve is a plot of the percentage of cells surviving after a 72-h continuous exposure to drug. {diamondsuit}, CTR1+/+ cells; {square}, CTR1-/- cells. Each point represents the mean of three independent experiments each performed with six replicate cultures. Vertical bars, S.E.M. Where S.E.M. bars are missing, they are smaller than the symbol.

 
Effect of the Loss of CTR1 on Sensitivity to the Growth-Inhibitory Effects of Copper, DDP, CBDCA, and L-OHP. Because the CTR1+/+ and CTR1-/- cells do not form discrete colonies when cultured on plastic, the effect of loss of CTR1 function on sensitivity to the cytotoxic effect of each drug was determined by quantifying the inhibition of proliferation during a 72-h exposure to increasing concentrations of drug. A 1-h exposure to drug, such as was used to assess the effect of the loss of CTR1 on accumulation, produced cytotoxicity only at drug concentrations unattainable in humans. Figure 2 depicts the inhibition of growth as a function of drug concentration using continuous exposure, which allowed the assessment of the effect of lower concentrations. The CTR1-/- cells were 1.4 ± 0.4 (mean ± S.E.M.)-fold more resistant to copper than their wild-type counterparts. It is interesting to note that the loss of CTR1 produced a larger degree of resistance to DDP than to copper; cells lacking CTR1 were 3.2 ± 0.4-fold resistant to DDP (95% confidence interval, 3.1-3.6). The CTR1-/- cells were only 2.0 ± 0.8 -fold resistant to CBDCA, and in a set of four experiments, this difference did not reach statistical significance. There was only a 1.7 ± 0.6-fold difference in sensitivity to L-OHP between the two types of cells, which was not statistically significant. Thus, consistent with the effect on the loss of CTR1 on drug uptake, loss of CTR1 produced different degrees of resistance to DDP, CBDCA, and L-OHP. It is interesting to note that although there was a marked difference in the uptake of 64Cu, the difference in copper IC50 values was not great. In contrast, for cells treated with DDP, there was a closer correspondence between the reduction in uptake and the increase in the IC50 value.


Figure 2
View larger version (8K):
[in this window]
[in a new window]

  		Fig. 2. Schematic drawings of the structure of DDP, CB-DCA, and L-OHP.

 

   Discussion
Top
 Abstract
 Materials and Methods
 Results
 Discussion
References
 
The isogenic pair of CTR1+/+ and CTR1-/- cells used in this study provides a powerful model in which to refine understanding of the role of CTR1 in the influx of the platinum-containing chemotherapeutic agents. Prior studies of the ability of CTR1 to mediate platinum drug accumulation in human cells have used forced expression of exogenous CTR1 and have been complicated by the presence of significant amounts of endogenous CTR1 (Beretta et al., 2004Go; Holzer et al., 2004Go; Song et al., 2004Go). As reported previously (Lee et al., 2002Go), the accumulation of copper in the CTR1-/- cells was found to be markedly reduced in the CTR1-/- cells when they were exposed to low concentrations of copper for 1 h. Accumulation in the CTR1-/- cells was just 5.7% of that in the CTR1+/+ cells. Loss of CTR1 function had a smaller but still substantial effect on the uptake of all three platinum-containing drugs when cells were exposed to 2 µM concentration of drug. At this concentration, accumulation was ~36% of that in the wild-type cells. In the case of DDP and CBDCA, this deficit in accumulation was still evident when cells were exposed to a 5-fold higher concentration; however, in the case of L-OHP, the deficit produced by the loss of CTR1 disappeared at the higher concentration. This suggests that CTR1 contributes importantly to the cellular uptake of all three drugs at the low concentrations typically attained in patient plasma, whereas at higher concentrations, L-OHP enters the cell predominantly via another mechanism.

S. cerevisiae express two high-affinity copper influx transporters, yCTR1 and yCTR3 (Petris, 2004Go). Knockout of yCTR1 in yeast in which yCTR3 was disabled reduced the accumulation of DDP, CBCDA, and L-OHP similar to the results obtained with the CTR1+/+ and CTR1-/- mouse embryo fibroblasts (Ishida et al., 2002Go; Lin et al., 2002Go). Thus, despite the fact that yCTR1 contains eight N-terminal copper-binding motifs while mCTR1 contains only two, both transporters seem to function similarly with respect to platinum drug accumulation.

In the mammalian cells, there was an association between the extent to which platinum drug uptake was impaired in the CTR1-/- cells and the extent to which sensitivity to the growth-inhibitory effect of the drug was reduced. The loss of CTR1 had a greater effect on the potency of DDP than CBDCA, but inspection of the curves in Fig. 1 indicates that even at very high drug concentrations, CTR1 was still important to the growth-inhibitory effect of these drugs. This suggests that other routes of entry for DDP and CBDCA into the cell do not become dominant over CTR1, even at high drug concentrations. In contrast, loss of CTR1 had less effect on the growth-inhibitory potency of L-OHP, consistent with the observation that the concentration required to inhibit growth was already greater than that at which the deficit in accumulation produced by loss of CTR1 had disappeared.

The fact that deletion of CTR1 did not completely eliminate DDP and CBDCA accumulation indicates that CTR1 is not the only route by which these drugs enter mammalian cells. This mirrors the situation for copper; even though the loss of CTR1 reduced copper uptake by 94%, and this transporter is essential for embryonic viability, copper nevertheless enters the cell in amounts sufficient to sustain growth. To date, no other transporter has definitively been shown to mediate the influx of copper in mammalian cells (Lee et al., 2002Go). Likewise, loss of CTR1 function reduced DDP and CBDCA uptake to only 36% of control, indicating that there is yet another mechanism by which DDP and CBDCA enter cells that has not yet been characterized.

The results of this study provide strong evidence that, at low concentrations, CTR1 mediates cellular accumulation of all three platinum-containing drugs currently used in patients but that L-OHP differs from DDP and CBDCA in that its dependence on CTR1 diminishes at higher concentrations. The concept that these drugs have different influx transporters is consistent with their different spectrum of action against various types of human cancer. The structures of DDP, CBDCA, and L-OHP are shown in Fig. 2. L-OHP differs from DDP and CBDCA in that it contains a bulky diaminocyclohexane ring, a feature that seems to make it a substrate for a non-CTR1-dependent entry mechanism at higher concentrations. Given the exquisite specificity of CTR1 for copper relative to other metal ions, it is surprising that any of these drugs is a substrate for the CTR1-mediated accumulation mechanism.


   Acknowledgements
 
We thank Dr. Dennis Theile for kindly providing the isogenic pair of CTR1+/+ and CTR1-/- cells used in this study. We acknowledge Dr. Goli Samimi, Michael Rasmussen, and Michael A. Gibson for assistance with cell growth assays, the Biomedical Sciences Graduate Program, and Claudette Zacharia for project management.


   Footnotes
 
This work was supported in part by grants CA95298 from the National Institutes of Health and DAMD17-03-1-0158 from the Department of Defense. The production of 64Cu at Washington University School of Medicine was supported by the National Cancer Institute grant R24-CA86307.

ABBREVIATIONS: DDP, cisplatin; L-OHP, oxaliplatin; CBDCA, carboplatin; CTR1, copper transporter 1.

Address correspondence to: Dr. Stephen B. Howell, Moores UCSD Cancer Center, 3855 Health Sciences Drive, Room 3344, La Jolla, CA 92093-0819. E-mail: showell{at}ucsd.edu


   References
Top
 Abstract
 Materials and Methods
 Results
 Discussion
 References
 
Andrews PA and Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2: 35-43.[Medline]

Andrews PA, Jones JA, Varki NM, and Howell SB (1990) Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma. Cancer Commun 2: 93-100.[Free Full Text]

Beretta GL, Gatti L, Tinelli S, Corna E, Colangelo D, Zunino F, and Perego P (2004) Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. Biochem Pharmacol 68: 283-291.[CrossRef][Medline]

Gately DP and Howell SB (1993) Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176.[Medline]

Holzer A, Samimi G, Katano K, Naedermann W, and Howell SB (2003) The role of human copper transporter hCTR1 in cisplatin uptake in human ovarian carcinoma cells. Proc Am Assoc Cancer Res 44: 923.

Holzer AK, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R, and Howell SB (2004) The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66: 817-823.[Abstract/Free Full Text]

Ishida S, Lee J, Thiele DJ, and Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99: 14298-14302.[Abstract/Free Full Text]

Katano K, Kondo A, Safaei R, Holzer A, Samimi G, Mishima M, Kuo Y-M, Rochdi M, and Howell S (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565.[Abstract/Free Full Text]

Kuo YM, Zhou B, Cosco D, and Gitschier J (2001) The copper transporter CTR1 provides an essential function in mammalian embryonic development. Proc Natl Acad Sci USA 98: 6836-6841.[Abstract/Free Full Text]

Lee J, Petris MJ, and Thiele DJ (2002) Characterization of mouse embryonic cells deficient in the Ctr1 high affinity copper transporter. J Biol Chem 277: 40253-40259.[Abstract/Free Full Text]

Lee J, Prohaska JR, and Thiele DJ (2001) Essential role for mammalian copper transporter Ctr1 in copper homeostasis and embryonic development. Proc Natl Acad Sci USA 98: 6842-6847.[Abstract/Free Full Text]

Lin X, Okuda T, Holzer A, and Howell SB (2002) The copper transporter CTR1 regulates cisplatin uptake in saccharomyces cerevisiae. Mol Pharmacol 62: 1154-1159.[Abstract/Free Full Text]

Naredi P, Heath DD, Enns RE, and Howell SB (1995) Cross-resistance between cisplatin, antimony potassium tartrate, and arsenite in human tumor cells. J Clin Investig 95: 1193-1198.[Medline]

Petris MJ (2004) The SLC31 (Ctr) copper transporter family. Pflueg Arch Eur J Physiol 447: 752-755.[CrossRef][Medline]

Romach EH, Zhao CQ, Del Razo LM, Cebrian ME, and Waalkes MP (2000) Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol Sci 54: 500-508.[Abstract/Free Full Text]

Safaei R, Holzer AK, Katano K, Samimi G, and Howell SB (2004a) The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 98: 1607-1613.[CrossRef][Medline]

Safaei R, Katano K, Samimi G, Naerdemann W, Stevenson JL, Rochdi M, and Howell SB (2004b) Cross-resistance to cisplatin in cells with acquired resistance to copper. Cancer Chemother Pharmacol 53: 239-246.[CrossRef][Medline]

Samimi G, Katano K, Holzer AK, Safaei R, and Howell SB (2004a) Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66: 25-32.[Abstract/Free Full Text]

Samimi G, Safaei R, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, and Howell SB (2004b) Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10: 4661-4669.[Abstract/Free Full Text]

Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279.[CrossRef][Medline]

Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, and Kuo MT (2004) Roles of copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and resistant cells. Mol Cancer Ther 3: 1543-1549.[Abstract/Free Full Text]

Tobey RA and Tesmer JG (1985) Differential response of cultured human normal and tumor cells to trace element-induced resistance to the alkylating agent melphalan. Cancer Res 45: 2567-2571.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
B. G. Blair, C. A. Larson, R. Safaei, and S. B. Howell
Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin
Clin. Cancer Res., July 1, 2009; 15(13): 4312 - 4321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
N. Pabla, R. F. Murphy, K. Liu, and Z. Dong
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity
Am J Physiol Renal Physiol, March 1, 2009; 296(3): F505 - F511.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. A. Larson, B. G. Blair, R. Safaei, and S. B. Howell
The Role of the Mammalian Copper Transporter 1 in the Cellular Accumulation of Platinum-Based Drugs
Mol. Pharmacol., February 1, 2009; 75(2): 324 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. D. Jandial, S. Farshchi-Heydari, C. A. Larson, G. I. Elliott, W. J. Wrasidlo, and S. B. Howell
Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1
Clin. Cancer Res., January 15, 2009; 15(2): 553 - 560.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.022624v1
70/4/1390    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holzer, A. K.
Right arrow Articles by Howell, S. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holzer, A. K.
Right arrow Articles by Howell, S. B.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics